Drug Profile
Research programme: therapeutics - NuMedii/Undisclosed company
Latest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator NuMedii; Undisclosed
- Developer NuMedii; Undisclosed Company
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for research development in Unspecified in USA
- 04 Oct 2016 Early research in Undefined indication in USA (unspecified route)